VIA HAND DELIVERY JULY 2ND, 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: NI et al.

Application Serial No.: 10/046,433 Art Unit: 1646

Filed: January 16, 2002 Examiner: O'Hara, E.

For: Human Tumor Necrosis Factor Receptors TR13 and TR14. Attorney Docket No.: **PF511P1**

#9
MQJ
7/31/03

First Supplemental Information Disclosure
Statement Pursuant to 37 C.F.R. § 1.56

Commissioner for Patents
P.O. Box 1450,
Alexandria, VA 22313-1450.

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of an claim of the subject application, Applicants hereby direct the Examiner's attention to the references EC-EG listed on the attached revised Form PTO/SB/08. Legible copies of references EC-EG are enclosed herewith.

The above information is presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 CFR § 1.104(a) concerning the PTO duty to consider and use any such information. It is respectfully requested that this information be considered during the prosecution of this application, and that it be made of record in the file history of the application.

Identification of the materials identified above is not to be construed an admission of any individual associated with the filing or prosecution of the subject application that

any such material is available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

Applicants respectfully request that the Examiner review the listed references and that the references be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97(c)(1), the Patent Office will consider this Supplemental Information Disclosure Statement if filed before the mailing date of a final Office Action under §1.113, a notice of allowance under §1.311, or an action that otherwise closes prosecution in this application provided that it is accompanied by a Statement as specified in § 1.97(e) or the fee as specified in § 1.17(p).

Accordingly, the undersigned certifies pursuant to 37 C.F.R. § 1.97(e)(1) that each item of information contained in this Supplemental Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of this Supplemental Information Disclosure Statement. In particular, the listed references were cited in a European Search Report (reference EG) mailed June 5, 2003, in connection with a corresponding international application.

In accordance with 37 C.F.R. § 1.97(c)(1), since it is believed that this Information Disclosure Statement is being filed before the mailing date of a final Office Action under §1.113, a notice of allowance under §1.311, or an action that otherwise closes prosecution in this application, and it is accompanied by a Statement as specified in § 1.97(e), no fee is believed due in connection herewith. However, should the Patent Office determine otherwise, please charge the required fee to Human Genome Science, Inc., Deposit Account No. 08-3425. A copy of this sheet is enclosed.

Respectfully submitted,

Dated: July 2, 2003

Lin J. Hymel (Reg. No. 45,414)
Attorney for Applicants
Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, MD 20850
(301) 251-6015 (telephone)

KKH/LJH/BM
Enclosures

Please type a plus sign (+) inside this box → +

PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known	
Application Number	10/046,433
Filing Date	January 16, 2002
First Named Inventor	NI et al.
Group Art Unit	1646
Examiner Name	O'Hara, E.
Attorney Docket Number	PF511P1

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.[1]	U.S. Patent Document Number	Kind Code[2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.[1]	Foreign Patent Document Office[3]	Number[4]	Kind Code[5] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
	EC	LATZA et al., *Eur. J. Immunol.*, 24: 677-683 (1994).	
	ED	LATZA et al., Tumor necrosis factor receptor superfamily member 4 precursor. SWISSPROT Accession No. P43489, 11-01-1995, annotation updated 09-15-2003.	
	EE	LOPAREV et al., Tumor necrosis factor receptor II homolog. SWISSPROT Accession No. O57116, 06-01-1998, annotation updated 02-01-2003.	
	EF	NAISMITH et al., *TIBS*, 23: 74-79 (1998).	
	EG	International Search Report from PCT/US00/19343 (06/05/03).	

Examiner Signature		Date Considered	

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.